


**CLAIMS**

1. Association comprising a compound favouring the lipid and carbohydrate metabolisms and an antioxidant agent.

5 2. Association according to claim 1, wherein the compound favouring the lipid and carbohydrate metabolisms is a compound of formula (I) :




wherein :

- X represents an oxygen or sulphur atom or a  $\text{CH}_2$  or  $\text{CH}^{\text{R}'2}$  group (wherein  $\text{R}'2$  together with  $\text{R}^2$  forms an additional bond),
- 10 •  $\text{R}^1$  and  $\text{R}^2$ , which may be identical or different, each represents a hydrogen atom, a linear or branched ( $\text{C}_1\text{-C}_6$ )alkyl group, an aryl group, an aryl- $(\text{C}_1\text{-C}_6)$ alkyl group in which the alkyl moiety may be linear or branched, an aryloxy group, an aryl- $(\text{C}_1\text{-C}_6)$ alkoxy group in which the alkoxy moiety may be linear or branched, a linear or branched ( $\text{C}_1\text{-C}_6$ )alkoxy group, a hydroxy group, an amino group, a linear or branched ( $\text{C}_1\text{-C}_6$ )alkylamino group or a dialkylamino group in which the alkyl moieties are linear or branched  $\text{C}_1\text{-C}_6$ ,  
15 or  $\text{R}^1$  and  $\text{R}^2$  together form an oxo, thioxo or imino group,  
it being possible furthermore for  $\text{R}^2$  to form with  $\text{R}'2$  an additional bond,
- 20 • A represents a  $(\text{C}_1\text{-C}_6)$ alkylene chain in which a  $\text{CH}_2$  group may be replaced by a hetero atom selected from oxygen and sulphur, by an  $\text{NR}_a$  group (wherein  $\text{R}_a$

represents a hydrogen atom or a linear or branched ( $C_1$ - $C_6$ )alkyl group, or by a phenylene or naphthylene group,

- B represents a linear or branched ( $C_1$ - $C_6$ )alkyl group or a linear or branched ( $C_2$ - $C_6$ )alkenyl group, those groups being substituted by a  $R^5$  group,

5 by a group of formula (II) :  (II) , or by a group of formula (III) :



in which groups:

- the representation ---- denotes that the bond is single or double,
- $R^5$  represents a  $\begin{array}{c} C-Z' \\ || \\ Z \end{array}$  group wherein Z represents a sulphur atom or an oxygen

10 atom and  $Z'$  represents an OR or  $NRR'$  group,

- and  $R^6$  represents a group  $\begin{array}{c} C-Z'' \\ || \\ Z \end{array}$  wherein  $Z''$  represents a  $Z'$  or R group,

(wherein R and  $R'$ , which may be identical or different, each represents a  $R''$  or  $-C(Me)_2COOR''$  group wherein  $R''$  represents a hydrogen atom or a linear or branched ( $C_1$ - $C_6$ )alkyl group, a linear or branched ( $C_2$ - $C_6$ )alkenyl group, a linear or branched ( $C_2$ - $C_6$ )alkynyl group, an aryl group, an aryl-( $C_1$ - $C_6$ )alkyl group in which

15 the alkyl moiety may be linear or branched, an aryl-( $C_2$ - $C_6$ )alkenyl group in which the alkenyl moiety may be linear or branched, an aryl-( $C_2$ - $C_6$ )alkynyl group in which the alkynyl moiety may be linear or branched, a heteroaryl group, a heteroaryl-( $C_1$ - $C_6$ )alkyl group in which the alkyl moiety may be linear or branched,

20 a heteroaryl-( $C_2$ - $C_6$ )alkenyl group in which the alkenyl moiety may be linear or branched, a heteroaryl-( $C_2$ - $C_6$ )alkynyl group in which the alkynyl moiety may be linear or branched, a ( $C_3$ - $C_8$ )cycloalkyl group, a ( $C_3$ - $C_8$ )cycloalkyl-( $C_1$ - $C_6$ )alkyl group in which the alkyl moiety may be linear or branched, or a linear or branched ( $C_1$ - $C_6$ )polyhaloalkyl group),

- $R^3$  and  $R^4$ , which may be identical or different, each represents a hydrogen atom, a halogen atom or a  $R$ ,  $OR$  or  $NRR'$  group (wherein  $R$  and  $R'$  are as defined hereinbefore),  
or  $R^3$  and  $R^4$  together with the carbon atoms carrying them, when they are carried by two adjacent carbon atoms, form a ring that has 5 or 6 ring members and that may contain a hetero atom selected from oxygen, sulphur and nitrogen,

5 • D represents:

10 a benzene nucleus, in which case X cannot represent a group  $\begin{array}{c} R^{12} \\ | \\ CH \end{array}$  as defined hereinbefore,

15 or D represents a pyridine, pyrazine, pyrimidine or pyridazine nucleus, those five nuclei being unsubstituted or substituted by from 1 to 3 identical or different

groups selected from  $R$ ,  $OR$ ,  $S(O)_nR$ ,  $C(Z)R$ ,  $-\begin{array}{c} OR \\ | \\ CH-R' \end{array}$ ,  $C(Z)OR$ ,  $NRR'$ ,  $C(Z)NRR'$ ,

$\begin{array}{c} R \\ | \\ -C=N-OR' \end{array}$ ,  $\begin{array}{c} R \\ | \\ -N-C(Z)R' \end{array}$ ,  $\begin{array}{c} R \\ | \\ -N-C(Z)OR' \end{array}$  (in which groups  $R$ ,  $R'$  and  $Z$  are

15 as defined hereinbefore and  $n$  is 0, 1 or 2), cyano, nitro and halogen atoms,

wherein:

- \* when A represents a  $CH_2$  group, B cannot represent a linear or branched  $(C_1-C_6)$ alkyl group substituted by a group  $-\begin{array}{c} C \\ || \\ Z \end{array}$ ,

- \* when the groups A and B are in the ortho position in relation to one another on the benzene nucleus carrying them, B cannot represent a linear or branched  $(C_2-C_6)$ -alkenylene group substituted by a group  $-\begin{array}{c} C \\ || \\ O \\ Z' \end{array}$ ,

- \* when A represents a group  $-\begin{array}{c} CH_2 \\ | \\ \text{C}_6\text{H}_4 \end{array}$ , B cannot represent a

20  $-CH_2\text{COOH}$  group,

- \* aryl is to be understood as a phenyl, naphthyl or biphenyl group, which groups may be partially hydrogenated,
- \* heteroaryl is to be understood as any mono- or bi-cyclic aromatic group containing from 5 to 10 ring members, which may be partially hydrogenated on one of the rings in the case of bicyclic heteroaryls, and which contains from 1 to 3 hetero atoms selected from oxygen, nitrogen and sulphur,

5 wherein the aryl and heteroaryl groups so defined may be substituted by from 1 to 3 groups selected from linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl, linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkoxy, carboxy, formyl, NR<sub>b</sub>R<sub>c</sub> (wherein R<sub>b</sub> and R<sub>c</sub>, which may be identical or different, each represents a 10 hydrogen atom, a linear or branched (C<sub>1</sub>-C<sub>6</sub>)alkyl group, an aryl group or a heteroaryl group), ester, amido, nitro, cyano, O-C(Me)<sub>2</sub>COOR" (wherein R" is as defined hereinbefore) and halogen atoms,

their enantiomers and diastereoisomers, and also addition salts thereof with a pharmaceutically acceptable acid or base.

15 3. Association according to claim 1, wherein the compound favouring the lipid and carbohydrate metabolisms is dimethyl 2-{4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3(2H)-yl)ethoxy]benzyl}malonate, its enantiomers and diastereoisomers, and also addition salts thereof with a pharmaceutically acceptable acid or base.

4. Association according to claim 1, wherein the antioxidant agent is coenzyme Q<sub>10</sub>.

20 5. Association according to claim 1, wherein the antioxidant agent is vitamin E.

6. Association according to claim 1, which is dimethyl 2-{4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3(2H)-yl)ethoxy]benzyl}malonate and coenzyme Q<sub>10</sub>.

7. Association according to claim 1, which is dimethyl 2-{4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3(2H)-yl)ethoxy]benzyl}malonate and vitamin E.

- 8. Pharmaceutical compositions comprising as active ingredient a compound favouring the lipid and carbohydrate metabolisms in association with an antioxidant agent according to one of claims 1 to 7, on their own or in combination with one or more pharmaceutically acceptable excipients.**
- 5      **9. Pharmaceutical compositions according to claim 8 for use in the manufacture of a medicament for the treatment and/or prevention of obesity.**
- 10     **10. Pharmaceutical compositions according to claim 8 for use in the manufacture of a medicament for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.**
- 10     **11. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity.**
- 15     **12. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by a therapeutic treatment.**
- 15     **13. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of obesity caused by treatment for type I or II diabetes.**
- 20     **14. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30.**
- 15     **15. Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment.**

**16.** Use of an association according to one of claims 1 to 7 in obtaining pharmaceutical compositions intended for the treatment and/or prevention of overweight characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes.